BioRestorative Granted Type B Meeting with FDA to Discuss Accelerated BLA Approval Pathway for BRTX-100 in Chronic Lumbar Disc Disease2025-11-1723%External coverage
BioRestorative Therapies Inc (BRTX) Q3 2025 Earnings Call Highlights: Strategic Advancements ...2025-11-1323%External coverage
Biorestorative Therapies, Inc. (BRTX) Reports Q3 Loss, Lags Revenue Estimates2025-11-1223%External coverage
BioRestorative Therapies Reports Third Quarter 2025 Financial Results and Provides Business Update2025-11-1223%External coverage
BioRestorative Therapies to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 20252025-11-053%External coverage